A patient with gout is prescribed allopurinol. After treatment, blood levels of hypoxanthine and xanthine rise moderately while uric acid falls significantly. What explains this pattern?
AAllopurinol blocks the conversion of AMP to IMP, reducing total purine flow through the pathway
BAllopurinol inhibits xanthine oxidase, preventing hypoxanthine and xanthine from being oxidized to the poorly soluble uric acid, so the more soluble precursors accumulate instead
CAllopurinol activates uricase, breaking uric acid down into soluble allantoin that is then excreted
DAllopurinol increases renal excretion of uric acid, causing precursors to accumulate upstream
Xanthine oxidase catalyzes the last two steps of purine degradation: hypoxanthine → xanthine → uric acid. Allopurinol (a structural analog of hypoxanthine) inhibits this enzyme, causing accumulation of hypoxanthine and xanthine upstream while uric acid production drops. This is the therapeutic goal — hypoxanthine and xanthine are more soluble than uric acid and won't precipitate in joints. Allopurinol has no effect on uricase (which humans lack) and does not act on the early steps of AMP deamination.
Question 2 Multiple Choice
Why does uric acid — rather than a more soluble compound — accumulate as the final product of purine catabolism in humans, making us uniquely vulnerable to gout?
AHuman xanthine oxidase is exceptionally efficient, preferentially producing uric acid over intermediate products
BThe kidney actively reabsorbs uric acid while excreting more soluble nitrogen products
CHumans lack the enzyme uricase, which most other mammals use to convert uric acid to the highly soluble allantoin
DThe purine ring structure is too stable for human enzymes to cleave, forcing oxidation to uric acid as the only available pathway
Most mammals possess uricase, which opens the purine ring and converts uric acid to allantoin — a far more soluble compound. Humans (and other great apes) lost functional uricase during evolution, making uric acid our metabolic dead end. Since we cannot cleave the purine ring open, we are stuck with uric acid's poor solubility (~6.8 mg/dL at physiological pH). Any condition that increases purine turnover risks pushing serum levels above this saturation threshold, causing crystal precipitation. Options A and B are secondary factors (renal handling affects levels, not the pathway endpoint); Option D is partly true but misses the uricase point.
Question 3 True / False
Gout attacks are caused by eating too many purine-rich foods, which directly generates uric acid crystals in joint fluid.
TTrue
FFalse
Answer: False
This oversimplifies the mechanism. Crystal formation requires serum uric acid to exceed its solubility threshold (~6.8 mg/dL), causing monosodium urate to precipitate. High-purine diet is one factor that can raise serum uric acid, but gout can arise from reduced renal excretion, rapid cell turnover (tumor lysis syndrome), or genetic overproduction — often without high dietary purine intake. The crystals form in joint fluid because peripheral joints (especially the big toe) are cooler, and urate solubility decreases with temperature. Diet is a modifiable risk factor, not the singular cause.
Question 4 True / False
Pyrimidines and purines are both degraded through pathways that ultimately produce uric acid in human metabolism, making uric acid the general endpoint for most nitrogen-containing nucleotide bases.
TTrue
FFalse
Answer: False
Only purines are degraded to uric acid. Pyrimidines (cytosine, thymine, uracil) are broken down through a completely different pathway that produces highly soluble end products: CO₂, ammonia (NH₃), and simple organic acids like beta-alanine and beta-aminoisobutyrate. These are excreted without difficulty. The unique problem with purines is that the double-ring structure cannot be cleaved open by human enzymes, forcing the pathway to terminate at uric acid. This distinction explains why purine — not pyrimidine — metabolism is clinically relevant to gout.
Question 5 Short Answer
Why does the big toe's first metatarsophalangeal joint experience gout attacks so frequently, and what does this tell us about the physical chemistry of uric acid?
Think about your answer, then reveal below.
Model answer: Uric acid's solubility decreases as temperature falls. The big toe's first metatarsophalangeal joint is one of the most peripheral, coolest joints in the body. As temperature drops, urate crosses its solubility threshold at lower serum concentrations, making monosodium urate crystals more likely to precipitate in cool peripheral joints than in warmer central ones. This reveals that gout localization is fundamentally a physical chemistry phenomenon: the same serum uric acid level that remains dissolved in warmer joints may supersaturate in the cooler periphery.
This temperature-solubility relationship also explains why gout attacks often occur at night (when overall body temperature drops) and why patients sometimes experience gout during illness-associated temperature changes. Understanding the physical chemistry directly explains clinical patterns and informs patient advice (keeping peripheral joints warm can reduce attack frequency).